Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...
Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...
A new vaccine is changing how doctors treat certain skin cancer patients, according to doctors in the ArkLaTex.
Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term ...
An Auckland woman who has spent months campaigning for cancer drug funding says the Petitions Select Committee’s response to ...
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results